Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anastozole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Arimidex 1mg + Nolvadex placebo |
| 2 | ACTIVE_COMPARATOR | Arimidex placebo + Nolvadex 20mg |
| 3 | ACTIVE_COMPARATOR | Arimidex 1mg + Nolvadex 20mg |
| Name | Type | Description |
|---|---|---|
| Anastozole (Arimidex) | DRUG | 1mg, orally, once daily |
| Tamoxifen (Nolvadex) | DRUG | 20mg, orally, once daily |
| Anastozole (Arimidex) placebo | DRUG | 1mg, orally, once daily |
| Tamoxifen (Nolvadex) placebo | DRUG | 20mg, orally, once daily |
Inclusion Criteria: * Patients with histologically proven operable invasive breast cancer * Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy * Women defined as post-menopausal Exclusion Criteria: * Patients in who...
Top 20 of 92 competitors
Anastozole is an investigational small molecule being developed for the treatment of breast cancer. It is currently in Phase 3 clinical development, though the specific trial listed has been completed. The drug is being studied in postmenopausal women aged 45 years and older.
Anastozole is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical research on this drug for the oncology therapeutic area, specifically targeting breast cancer.
Anastozole is in Phase 3 clinical development for breast cancer. The Phase 3 trial, known as ATAC, has been completed. As an investigational drug, it has not yet been approved by regulatory authorities and remains under clinical investigation.
Anastozole has one completed Phase 3 clinical trial registered under NCT00849030, titled 'ATAC - Arimidex, Tamoxifen Alone or in Combination'. This randomized, double-blind, active-controlled study enrolled 9,358 female participants with breast cancer.
Anastozole is the drug being studied in the ATAC trial, which compares Arimidex, tamoxifen, or a combination of both. Anastozole is the investigational drug name, while Arimidex is a brand name for anastrozole, a separate drug used in the trial as a comparator.